Devonian Health Group Plans NYSE American Listing with Public Offering

Devonian Health Group Inc., a biopharmaceutical company focused on developing therapies for fibro-inflammatory diseases, has announced its intention to list its common shares on the NYSE American market. The company plans to conduct an underwritten public offering concurrent with the listing.

The proposed listing and offering are intended to enhance Devonian Health Group's access to capital markets and increase its public profile. The company's current development pipeline consists of therapies targeting fibro-inflammatory conditions, with its programs in the clinical stage.

Devonian Health Group is currently traded on the TSX Venture Exchange under the symbol GSD and on the OTCQB market under the symbol DVHGF. The transition to the NYSE American aims to provide greater liquidity and visibility for its investors.

Details regarding the number of shares to be offered and the proposed price range have not yet been disclosed. The company stated the proceeds from the offering will be used to fund ongoing clinical trials and general corporate purposes.